FLOW, SURMOUNT-OSA trial symposia among highlights at ADA Scientific Sessions
Click Here to Manage Email Alerts
Key takeaways:
- The ADA 84th Scientific Sessions will kick off Friday in Orlando.
- New data on tirzepatide, semaglutide, inhaled insulin and SGLT2 inhibitors will be presented at the meeting.
Presentations on the SURMOUNT-OSA, FLOW, INHALE-3 and TIGHT trials are among the many highlights at the American Diabetes Association’s 84th Scientific Sessions.
The ADA Scientific Sessions will take place Friday through Monday at the Orange County Convention Center in Orlando. The conference is a hybrid meeting, with virtual attendees able to view select sessions live on the online meeting platform. Livestreamed sessions will be available on demand beginning approximately 1 day after they take place. On-demand access will be available until Aug. 26.
The hybrid format has multiple benefits, according to Marlon Pragnell, PhD, vice president of research and science at the ADA. In addition to allowing people unable to attend the conference in person the opportunity to view sessions, a hybrid format gives in-person attendees an opportunity to view sessions they may have missed.
“There are a lot of exciting sessions, many concurrent” Pragnell told Healio. “People can attend their favorites and then watch all the other sessions on demand for up to 2 months after the conference”
This year’s program retains the same format innovations from last year, when the ADA shortened the meeting to 4 days, cut the length of the longest symposia sessions from 2 hours to 90 minutes and increased the number of panel discussions, debates and ask-the-expert sessions.
“One of the key things we’re really focusing on is engagement,” Pragnell said. “We’re reminding chairs and speakers to make sure there’s a lot of time for question and answers, because that’s one the most exciting part of the session. The audience gets to engage and deepen their understanding.”
Attendees will get a look at late-breaking data from several diabetes, obesity and cardiometabolic trials. One of the top presentations will focus on the FLOW trial, in which adults with type 2 diabetes and chronic kidney disease were randomly assigned to once-weekly semaglutide (Ozempic, Novo Nordisk) or placebo. As Healio previously reported in top-line results from the trial, adults receiving semaglutide had a 24% lower risk for kidney disease progression, cardiovascular mortality and kidney mortality compared with placebo. Findings from FLOW were originally presented at the European Renal Association Congress in May. Pragnell said the presentation at the ADA Scientific Sessions will include new data from the trial that was not previously presented.
Another medication, tirzepatide (Mounjaro/Zepbound, Eli Lilly), will be highlighted during a symposium on the SURMOUNT-OSA trial and the role of tirzepatide for treating obesity-related obstructive sleep apnea. As Healio previously reported, top-line data from the SURMOUNT-OSA trial found tirzepatide reduced sleep apnea severity for adults with moderate to severe sleep apnea plus obesity.
Inhaled insulin will be the focus of another symposium as researchers discuss data from the INHALE-3 trial. The trial compares inhaled insulin (Afrezza, MannKind) with a rapid-acting analog insulin among people using automated insulin delivery or receiving multiple daily insulin injections.
Other highlights at this year’s meeting include:
- The meeting will kick off with a keynote address by Robert M. Califf, MD, commissioner of the FDA. Califf’s address will focus on the dissociation between technology advances and health outcomes for diabetes in the U.S.
- Attendees will get their first peek at findings from the CATALYST study during a session on the prevalence of hypercortisolism in difficult-to-control type 2 diabetes. Data will be presented on part one of the study, which focuses on measuring the prevalence of hypercortisolism among adults with type 2 diabetes and an HbA1c of 7.5% or higher despite optimized therapy. As Healio previously reported, 24% of the first 700 adults to enroll in the study had hypercortisolism.
- The use of continuous glucose monitoring in the hospital will be examined during a symposium on the TIGHT trial. The study is a randomized trial comparing intensive glucose management with CGM to usual care for hospitalized adults with type 2 diabetes.
- Researchers will present findings from the ATTEMPT trial, which examines the use of SGLT2 inhibitors among adolescents with type 1 diabetes. The presentation will include data on glycemic and renal outcomes.
The Scientific Sessions will also feature several professional development sessions as well as a networking reception on Friday evening in the exhibit hall that is open to all attendees. Pragnell said the networking and connection aspects of the meeting are just as important as the presentations.
“We’re thrilled to see everyone connecting at the Friday evening networking reception. It’s also great to see people enjoying side conversations everywhere in the hallways, poster and exhibit halls,” Pragnell said. The program is packed with so much great science, but people always make time for this hugely important part of the Scientific Sessions experience.”
Healio will provide coverage live from the ADA Scientific Sessions, including reports on the sessions, on-site video interviews and more. For more information on the program and registration, visit https://professional.diabetes.org/scientific-sessions.
Collapse
Healio Interviews
Click Here to Manage Email Alerts